Home › NDC Lookup › RxCUI directory › RxCUI 2628223

Daprodustat 2 MG Oral Tablet — RxCUI 2628223

RxNorm drug concept · Semantic clinical drug
RxCUI 2628223 Semantic clinical drug · SCD ● Current RxNorm concept 5 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2628223
Official nameDaprodustat 2 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped5
Package NDCs mapped5
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Daprodustat: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Jesduvroq is designed to treat anemia — low red blood cell levels — that comes from chronic kidney disease in people on dialysis. It works by prompting your body to produce more of...
  • What exactly is Jesduvroq supposed to do for me?
  • Daprodustat starts boosting your body's erythropoietin within about 6 to 8 hours of your first dose. You'll start seeing new red blood cells appear in your blood within 1 to 2 week...
  • The most common ones are high blood pressure, belly pain, and dizziness. But the most serious risk — one serious enough to be on a warning label — is blood clots. This includes clo...
📖 Read our full Daprodustat guide →

🕸️ Concept Web — How Daprodustat 2 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Daprodustat 2 MG Oral Tablet RxCUI 2628223

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Daprodustat 2628210
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Jesduvroq 2628216
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Daprodustat Oral Tablet 2628214
    • Daprodustat Oral Product 2628212
    • Daprodustat Pill 2628213
    • Daprodustat Oral Tablet [Jesduvroq] 2628220
    • Jesduvroq Oral Product 2628218
    • Jesduvroq Pill 2628219
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Daprodustat 2 MG SCDC · 2628222
  • Daprodustat Oral Tablet SCDF · 2628214
  • Daprodustat Oral Product SCDG · 2628212
  • Daprodustat Pill SCDG · 2628213

Brand-Name Concepts

  • Daprodustat 2 MG Oral Tablet [Jesduvroq] SBD · 2628225
  • Daprodustat 2 MG [Jesduvroq] SBDC · 2628224
  • Daprodustat Oral Tablet [Jesduvroq] SBDF · 2628220
  • Jesduvroq Oral Product SBDG · 2628218
  • Jesduvroq Pill SBDG · 2628219
  • Jesduvroq BN · 2628216

📦 FDA Products & Package NDCs

5 products · 5 package NDCs
5 package NDCs map to RxCUI 2628223 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00173-0897-13 30 TABLET, FILM COATED in 1 BOTTLE (0173-0897-13) Jesduvroq GlaxoSmithKline LLC 2023-02-01
00173-0903-13 30 TABLET, FILM COATED in 1 BOTTLE (0173-0903-13) Jesduvroq GlaxoSmithKline LLC 2023-02-01
00173-0906-13 30 TABLET, FILM COATED in 1 BOTTLE (0173-0906-13) Jesduvroq GlaxoSmithKline LLC 2023-02-01
00173-0911-13 30 TABLET, FILM COATED in 1 BOTTLE (0173-0911-13) Jesduvroq GlaxoSmithKline LLC 2023-02-01
00173-0914-13 30 TABLET, FILM COATED in 1 BOTTLE (0173-0914-13) Jesduvroq GlaxoSmithKline LLC 2023-02-01
Observed labelers: GlaxoSmithKline LLC (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.